Equifax Canada Reports-National Delinquency Rates Decline

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Equifax Canada Reports-National Delinquency Rates Decline to Their Lowest Levels Ahead of the Holidays

TORONTO, ONTARIO--(Marketwired - Dec. 2, 2015) - On average, Canadians' ability to pay back loans has never been better, according to Equifax Canada's Q3 2015 National Consumer Credit Trends Report. The report now pegs the 90+ delinquency rate (excluding mortgages) at its lowest level ever at 1.05 per cent, a decrease of 4.3 per cent when compared to the same quarter last year.

The decrease in the national 90+ delinquency rate was largely driven by the continued changes in Ontario. Improvements were also seen in Quebec and eastern provinces in the third quarter. Notable increases, however, did occur in the oil-producing western provinces and Newfoundland.

"During holiday season, as always, people should make smart debt and spending decisions based on their individual circumstances," said Regina Malina, Senior Director of Decision Insights at Equifax Canada. "Delinquency rates are an indicator that we follow closely and we are now seeing a negative effect in western Canada. The same holds true in Newfoundland - essentially anywhere in the country where the economy is impacted by oil."

In the previous quarter, the 90+ day delinquency rate for Canadians aged 65+ rose for the first time since 2010. In the third quarter, all demographic groups showed a decrease with respect to delinquency rates. The average debt within the 65+ age segment, however, is still increasing at the fastest rate in Q3 2015.

Major City Analysis

Debt (excluding mortgages) & Delinquency Rates
Average Debt Delinquency Rate Change Year-over-Year (Q3 2015 vs. Q3 2014)
Calgary $28,355 8.5%
Edmonton $26,420 7.9%
Halifax $22,889 -4.6%
Montreal $16,588 -3.5%
Ottawa $20,776 -3.5%
Toronto $19,780 -13.2%
Vancouver $23,395 -11.6%
St. John's $24,219 12.4%

Province Analysis

Debt (excluding mortgages) & Delinquency Rates
Average Debt Delinquency Rate Change Year-over-Year (Q3 2015 vs. Q3 2014)
Ontario $20,881 -10.9%
Quebec $17,985 0.3%
Nova Scotia $21,334 -1.8%
New Brunswick $21,779 -6.6%
PEI $21,059 -6.9%
Newfoundland $22,360 5.8%
Eastern Region $21,684 -2.7%
Alberta $27,490 13.4%
Manitoba $17,803 3.7%
Saskatchewan $23,671 8.5%
British Columbia $23,012 -10.9%
Western Region $24,165 1.1%
Canada $21,312 -4.3%

The numbers of bankruptcies in Alberta, Saskatchewan and Newfoundland & Labrador also increased in the third quarter. The average bankruptcy balance increased in Q3 2015 when compared to the same quarter last year, mainly driven by the younger segments, and all regions but Ontario. Overall, however, consumer bankruptcies were down 9.3 per cent when compared to the same quarter last year.

Total reported consumer debt is now at $1.587 trillion compared to $1.568 trillion in Q2 2015 and $1.513 trillion a year ago, which represents an increase of 1.24 per cent and 4.92 per cent. On a debt classification basis, the installment loan, auto loan and national credit card sectors showed significant increases of 8.1 per cent, 5.1 per cent year-over-year, and 2.6 per cent respectively. The average consumer debt is $21,312, which increased by 2.0 per cent versus the same quarter last year.

"Consumer debt levels continue to rise and those numbers are sure to increase following the holidays," added Malina. "However, despite other market research we've seen predicting a boom in spending over the holidays, we expect most Canadians will continue to manage their spending wisely. Demand for new credit has eased off."

Data for this report, including scores, are sourced from Equifax Canada, the repository of the majority of credit transactions that occur in Canada. There are over 25 million unique Equifax consumer credit files. Transaction volumes for data are estimated at 105 million per month. Information provided in this report was adjusted to ensure that quarterly data reflects the results as of the last month of each quarter.

Click HERE for more information.

About Equifax

Equifax is a global leader in consumer, commercial and workforce information solutions that provide businesses of all sizes and consumers with insight and information they can trust. Equifax organizes and assimilates data on more than 600 million consumers and 81 million businesses worldwide. The company's significant investments in differentiated data, its expertise in advanced analytics to explore and develop new multi-source data solutions, and its leading-edge proprietary technology enable it to create and deliver unparalleled customized insights that enrich both the performance of businesses and the lives of consumers.

Headquartered in Atlanta, Equifax operates or has investments in 19 countries and is a member of Standard & Poor's (S&P) 500® Index. Its common stock is traded on the New York Stock Exchange (NYSE) under the symbol EFX. In 2015, Forbes named Equifax one of the World's 100 Most Innovative companies; Bloomberg BusinessWeek nominated it as one of its Top 50 companies; its CIO was named one of the top 100 by CIO magazine; the company ranked 16 th in the Fintech 100 list; and it was recognized as a top 20 company to work for by the Atlanta Journal-Constitution and was named a 2015 InformationWeek Elite 100 Winner. For more information, please visit www.equifax.com .

Andrew Findlater SELECT Public Relations afindlater@selectpr.ca (416) 659-1197 Tom Carroll Media Relations Equifax Canada MediaRelationsCanada@equifax.com (416) 227-5290
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 397

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
BAIC FOTON Eyes African Market with Strategic Moves

Updated Category News Views 149

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 205

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 606

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Updated Category News Views 288

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 196

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
Hims & Hers Faces FTC Heat: Investor Class Action Looms

Updated Category News Views 245

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 258

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 223

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 322

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading

Top 5 Most Recently Viewed Articles

Care Synergy and RCC Medical Equipment Launch New Partnership

Updated Category News Views 320

Care Synergy and RCC Medical Equipment Form Joint Venture In an exciting development for healthcare services, Care Synergy and RCC Medical Equipment Co. have announced their plans to create a strategic joint venture aimed at improving healthcare delivery in the Colorado Front Range region. This partnership will leverage the strengths of both organizations to provide...

Continue Reading
Revitalizing China's Tourism with High-Tech Cultural Experiences

Updated Category News Views 217

Revitalizing China's Tourism Through High-Tech Cultural Experiences China's tourism industry is undergoing an exciting transformation, fueled by the innovative use of advanced technology paired with its rich cultural heritage. A remarkable example is in Chongqing Municipality, where the city's skyline has become a vibrant showcase of cultural stories, highlighted by...

Continue Reading
Intriguing Insights into United States Steel Options Trades

Updated Category News Views 111

Analyzing Unusual Options Activity in United States Steel Recently, there's been notable market activity where investors with deep pockets are taking a more bearish stance on United States Steel (X). This trend is definitely something for retail traders to pay attention to, especially when navigating the complexities of the stock market. Today's options history unveiled...

Continue Reading
Mesoblast's Operational Highlights and Financial Insights Unveiled

Updated Category News Views 185

Mesoblast Limited's Webcast for Financial Results On a recent occasion, Mesoblast Limited (NASDAQ: MESO; ASX: MSB), a pioneer in allogeneic cellular medicine for inflammatory diseases, announced a webcast to delve into their operational achievements and financial metrics for the half year concluding December 31, 2024. Details of the Webcast Event The engaging webcast is...

Continue Reading
Investors of DXC Technology Prepare for Class Action Lawsuit

Updated Category News Views 77

Investors of DXC Technology Company Take Action In recent months, investors who purchased common stock from DXC Technology Company (NYSE: DXC) have been given a significant opportunity to participate in a class action lawsuit. This situation arises from allegations of securities fraud that are said to have affected many individuals who bought shares during specific key...

Continue Reading